低分子肝素钙改良皮下注射抗血栓的临床效果  

Clinical effect of anti-thrombosis on improved subcutaneous injection of Low Molecular Weight Heparin Calcium

作　　者：金大鹏[1] 王文丰[1] 赵秀娟[2] 王海燕[3] JIN Dapeng WANG Wenfeng ZHAO Xiujuan WANG Haiyan(Department of Cardiology, Affiliated Hospital of Chengde Medical College, Hebei Province, Chengde 067000, China Department of Infection, Langfang People＇s Hospital of Hebei Province, Hebei Province, Langfang 065000, China Department of Medical Examination, Affiliated Hospital of Chengde Medical College, Hebei Province, Chengde 067000, China)

机构地区：[1]承德医学院附属医院心脏内科,河北承德067000 [2]河北省廊坊市人民医院感染科,河北廊坊065000 [3]承德医学院附属医院体检科,河北承德067000

出　　处：《中国医药导报》2017年第28期65-68,共4页China Medical Herald

基　　金：河北省承德市科技支撑计划项目(20157066)

摘　　要：目的观察低分子肝素钙改良皮下注射抗血栓的临床效果及并发症。方法选取2015年3月~2017年2月承德医学院附属医院门诊接诊且需接受低分子肝素钙抗血栓治疗的96例患者为研究对象,根据用药方式进行分组,研究组48例患者采用低分子肝素钙改良皮下注射方式,对照组48例患者则仅按照常规的方式进行注射治疗。观察两组治疗前后血小板聚集功能、血常规以及凝血功能情况,比较两组并发症、治疗满意度等。结果两组治疗前后血小板计数(PLT)、活化部分凝血活酶时间(APTT)、血小板最大聚集率(PAGm-ADP)、凝血酶原时间(PT)组间比较,差异无统计学意义(P>0.05)。两组治疗后PAGm-ADP均低于治疗前,差异有统计学意义(P<0.05)。研究组皮下出血发生率为6.25%,低于对照组的27.08%,差异有统计学意义(P<0.05)。研究组硬结发生率为0.00%,低于对照组的6.25%,差异有统计学意义(P<0.05)。研究组治疗总满意度为93.75%,高于对照组的81.25%,差异有统计学意义(P<0.05)。结论改良皮下注射流程应用于接受低分子肝素钙抗血栓治疗的患者,可显著减少并发症发生风险,确保临床疗效,提高患者的治疗满意度。Objective To observe clinical effect and complication of anti-thrombosis on improved subcutaneous injection of Low Molecular Weight Heparin Calcium. Methods 96 patients treated in Outpatient, Affiliated Hospital of Chengde Medical College and need to accept Low Molecular Weight Heparin Calcium antithrombotic therapy from March 2015 to February 2017 were selected as research objects. All patients were grouped according to treatment method. Low Molecular Weight Heparin Calcium modified subcutaneous injection was used in study group （48 cases）, conventional injection treatment was applied in control group （48 cases）. The platelet aggregation function, blood routine and coagulation function between two groups were observed before and after treatment. Complications, treatment satisfaction between two groups were compared. Results There were no significant difference in PLT, APTF, PAGm-ADP, PT levels between two groups before treatment and after treatment （P 〉 0.05）. PAGm-ADP of two groups after treatment were lower than before treatment, the differences were statistically significant （P 〈 0.05）. The incidence rate of subcutaneous hemorrhage was 6.25% in study group, lower than that in control group （27.08%）, the difference was statistically significant （P 〈 0.05）. The incidence rate of induration was 0.00% in study group, lower than that in control group （6.25%）, the difference was statistically significant （P 〈 0.05）. Total satisfaction rate of study group was 93.75%, higher than that of control group （81.25%）, the difference was statistically significant （P 〈 0.05）. Conclusion The improved subcutaneous injection procedure applied in patients receiving Low Molecular Weight Heparin Calcium antithrombotic therapy can significantly reduce the risk of complication, ensure clinical efficacy, improve treatment satisfaction of patient.

关 键 词：皮下注射 抗血栓 低分子肝素钙 应用价值 

分 类 号：R453[医药卫生—治疗学]